MINITRAN PATCH

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

NITROGLYCERIN

可用日期:

VALEANT CANADA LP / VALEANT CANADA S.E.C.

ATC代码:

C01DA02

INN（国际名称）:

GLYCERYL TRINITRATE

剂量:

0.4MG

药物剂型:

PATCH

组成:

NITROGLYCERIN 0.4MG

给药途径:

TRANSDERMAL

每包单位数:

30/100

处方类型:

Ethical

治疗领域:

NITRATES AND NITRITES

產品總結:

Active ingredient group (AIG) number: 0103615009; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2021-03-19

产品特点

_ _
_Product Monograph – MINITRAN_
_®_
_ _
_ _
_Page 1 of 20_
PRODUCT MONOGRAPH
MINITRAN
® 0.2 MG/HR
MINITRAN
® 0.4 MG/HR
MINITRAN
® 0.6 MG/HR
Nitroglycerin
Transdermal Delivery System
Rated Release _in vivo_ 0.2, 0.4, and 0.6 mg/hour
Antianginal
Valeant Canada LP
2150 St-Elzear Blvd., West
Laval (Quebec) H7L 4A8
Canada
Date of Preparation:
March 6, 2013
Date of Revision:
August 19, 2015
Submission Control No: 184516
_ _
_Product Monograph – MINITRAN_
_®_
_ _
_ _
_Page 2 of 20_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................12
SPECIAL HANDLING INSTRUCTIONS
.......................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACE